Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
huC242-DM4 in metastatic gastric or GE junction cancer
NCT00620607Phase 2Withdrawn
- Sponsor
- ImmunoGen
- Start
- May 2007
- Primary completion
- May 2010
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cantuzumab ravtansine in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by ImmunoGen. Planned start May 2007; status: withdrawn.
02
Drugs
cantuzumab ravtansine
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00620607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00620607.